<DOC>
	<DOCNO>NCT00243503</DOCNO>
	<brief_summary>The current study evaluate : Overall response rate combination trastuzumab SU011248 metastatic locally recurrent breast cancer ; evaluate safety tolerability combination ; measure duration tumor control survival ; ass patient report outcome ; ass PK combination trastuzumab compare efficacy safety .</brief_summary>
	<brief_title>Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>A diagnosis breast cancer evidence 1 ) unresectable , locally recurrent , 2 ) metastatic disease . HER2 positive disease ( 3+ immunohistochemistry [ IHC ] FISHpositive ) Candidate treatment trastuzumab . Prior treatment trastuzumab or/ lapatinib neoadjuvant , adjuvant metastatic disease set permit . Treatment hormone therapy adjuvant and/or advance disease set permit . Prior treatment &gt; 1 regimen cytotoxic therapy advance disease set . Adjuvant chemotherapy permit Prior exposure trastuzumab patient develop severe hypersensitivity reaction . Prior treatment SU11248 clinical trial . Uncontrolled brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast Cancer Metastatic</keyword>
</DOC>